The PLK1 inhibitor BI2536 and its derivative BI6727 inhibit tumor growth in vitro and in the clinical setting [19,20], suggesting that a PLK1 inhibitor could be a monotherapy for cancer treatment. The gene discussed is PLK1; the disease is neoplasm.